ReviewMolecular and cellular pediatrics2016
Mechanism of human rhinovirus infections.
Review in Molecular and cellular pediatrics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- ColdZyme® reduces viral load and upper respiratory tract infection duration and protects airway epithelia from infection with human rhinoviruses.The Journal of physiology · 2025Trial
- Airway epithelia clear rhinovirus infection via two waves of cell extrusion.Science advances · 2026Article
- Leveraging perturbations to infer the population dynamics of human rhinovirus and interaction of influenza A virus.PLoS computational biology · 2026Article
- Target-Based Antiviral Drug Development Against Human Respiratory Viruses.Pathogens (Basel, Switzerland) · 2026Review
- Leveraging perturbations to infer the population dynamics of human rhinovirus and interaction of influenza A virus.medRxiv : the preprint server for health sciences · 2026Article
- Host cell entry receptors as pharmacological targets in respiratory viral infections: from biology to clinical translation.Frontiers in cellular and infection microbiology · 2026Review
- Article
- The long reach of influenza and other respiratory viruses: from acute epithelial injury to post-viral lung disease.Clinical microbiology reviews · 2025Review
- Creation of a Novel Coding Program to Identify Genes Controlled by miRNAs During Human Rhinovirus Infection.Methods and protocols · 2025Article
- Nebulized 2-deoxylated glucose analogues inhibit respiratory viral infection in advanced in vitro airway models.Scientific reports · 2025Article
- Quercetin-3-Methyl Ether Induces Early Apoptosis to Overcome HRV1B Immune Evasion, Suppress Viral Replication, and Mitigate Inflammatory Pathogenesis.Biomolecules & therapeutics · 2025Article
- Interplay between respiratory viruses and cilia in the airways.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Platelet Activating Factor Receptor and Intercellular Adhesion Molecule-1 Expression Increases in the Small Airway Epithelium and Parenchyma of Patients with Idiopathic Pulmonary Fibrosis: Implications for Microbial Pathogenesis.Journal of clinical medicine · 2024Article
- Maltodextrin-Nanoparticles as a Delivery System for Nasal Vaccines: A Review Article.Pharmaceutics · 2024Review
- Effects of Contagious Respiratory Pathogens on Breath Biomarkers.Antioxidants (Basel, Switzerland) · 2024Article
- Exosome-mediated regulation of inflammatory pathway during respiratory viral disease.Virology journal · 2024Review
- Viral infection in chronic otitis media with effusion in children.Frontiers in pediatrics · 2023Article
- Host-directed therapy with 2-deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2.Journal of virus eradication · 2022Article
- Changes in the pattern and disease burden of acute respiratory viral infections before and during the COVID-19 pandemic.Osong public health and research perspectives · 2022Article
- Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.Pharmaceutical research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
About 150 human rhinovirus serotypes are responsible for more than 50 % of recurrent upper respiratory infections. Despite having similar 3D structures, some bind members of the low-density lipoprotein receptor family, some ICAM-1, and some use CDHR3 for host cell infection. This is also reflected in the pathways exploited for cellular entry. We found that even rhinovirus serotypes binding the same receptor can travel along different endocytic pathways and release their RNA genome into the cytosol at different locations. How this may account for distinct immune responses elicited by various rhinoviruses and the observed symptoms of the common cold is briefly discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.